查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球血吸虫病药物市场2022-2029
市场调查报告书
商品编码
1140669

全球血吸虫病药物市场2022-2029

Global Schistosomiasis Drugs Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

2021 年血吸虫病药物市场价值 7040 万美元。预计在预测期内(2022-2029 年)将以 3.8% 的复合年增长率增长。

血吸虫病，又称吸血吸虫、血吸虫、片山热，是由寄生虫血吸虫引起的急慢性疾病。该病通过水传播感染传播。血吸虫寄生虫生活在河流、湖泊、水上公园、池塘、水池、市政水域和溪流中。感染血吸虫、曼氏血吸虫和日本血吸虫会导致人类疾病，但鲜为人知的湄公河沙门氏菌和插间沙门氏菌也会引起疾病。然而，儘管在美国尚未发现导致血吸虫病的蠕虫，但它感染了全球超过 2 亿人。感染通过直接接触受感染的动物或人而传播。 2018年，78个国家报告了血吸虫病病例。

血吸虫病的症状是由身体对虫卵的反应引起的。症状包括腹部绞痛、腹泻、便血、尿血、呕吐、肝臟肿大、发烧、肾臟损伤、虚弱、皮疹和身体疼痛。其他慢性症状包括生殖器病变、阴道出血和外阴结节。建议由医疗保健专业人员重复测试以检查粪便和尿液中的血吸虫病。聚合□链反应 (PCR) 测试和血液测试也可以帮助诊断血吸虫病。如果尿液或粪便中没有发现卵子，建议进行其他检查，例如内窥镜检查、结肠镜检查、超声、肝活检和 MRI，以获得更好的诊断。如果不及时治疗，偏头痛会导致并发症，如心肺、胃肠道、中枢神经系统、脾臟、肝臟、细菌感染、尿潴留，甚至死亡。

市场动态

全球血吸虫病药物市场的增长是由血吸虫病患病率上升、医疗保健设施不足以及发展中国家缺乏安全饮用水等因素推动的。

血吸虫病患病率上升正在推动市场增长

超过 1.4 亿人(其中 90% 生活在非洲)感染了血吸虫病。在该疾病流行的 76 个国家，估计有 7 亿人因农业、家庭和娱乐活动接触受感染的水而面临感染风险。全世界每年有 200,000 人死于血吸虫病。一些国家的感染已经停止。据世界卫生组织(WHO)估计，2019 年约有 2.366 亿人需要血吸虫病预防性治疗，其中超过 1.054 亿人据报导接受了治疗。

因此，血吸虫病的日益流行刺激了私人製造商和研究机构对其治疗的研究和开发。几项临床试验正在进行中，以扩大血吸虫病药物的潜力。

用于治疗血吸虫病的新型疫苗的不断开发有望推动市场增长

2021 年 6 月 1 日，国际疫苗研究所 (IVI) 授予比尔和梅琳达·盖茨基金会的赠款，用于设计和开发适用于偏头痛疫苗 Ib/IIa 期临床试验的方案。这种疫苗提供了一种具有成本效益和安全的疫苗。几种疫苗正在开发中，正在申请专利的疫苗也已在中国、印度和巴西申请。新疫苗开发旨在开发这种疫苗并以可承受的价格将其分发给受感染的人。预计这一发展将在预测期内推动血吸虫病药物市场的增长。

对血吸虫病预防的高需求推动了血吸虫病药物市场

根据世界卫生组织 (WHO) 2018 年的数据，超过 78 个国家长期感染血吸虫病，其中 52 人需要预防性化疗。世卫组织估计，2018 年将有约 2.292 亿人需要预防性化疗，其中约 1.244 亿为学龄儿童。

然而，该药物的高成本和严格的审批程序正在抑制市场增长。庞大的患者群体和未满足的医疗需求预计将为市场增长提供有利可图的机会。

流行病学

急性和慢性血吸虫感染在美国并不常见。然而，随着估计有 400,000 名感染者迁移到美国，没有足够大的易感蜗牛物种或慢性感染者进入淡水的水库。致病性偏头痛可以在人类宿主中长期存活和復制。因此，旅行或移民的人可能会因急性或慢性血吸虫病和相关的终末器官并发症的活跃病例而到急诊室就诊。许多感染者仍然没有症状。由于暴露后会产生强烈的免疫反应，因此急性症状在未接种疫苗的旅行者中更为常见。

在全球范围内(不包括美国)，血吸虫病是导致死亡和发病的主要原因。由曼氏血吸虫引起的肠道血吸虫病在加勒比国家(即波多黎各、圣卢西亚、蒙特塞拉特、安提瓜、马提尼克、瓜德罗普、多米尼加共和国)、东地中海国家、南美国家(即巴西、委内瑞拉、苏里南)很常见。大约 52 个国家，包括非洲的大部分地区。

S intercalatum 分布于中非热带雨林内的大约 10 个国家。日本血吸虫在西太平洋地区的四个国家(中国、印度尼西亚、菲律宾和泰国)流行。 S mekongi 是东南亚湄公河流域(柬埔寨、老挝、泰国)的地方病。血吸虫尿路血吸虫病感染了非洲和东地中海的 54 个国家。

大约 74 个国家的超过 2.07 亿人感染了血吸虫病。其中，约 60% 有疾病症状，例如因感染引起的器官特异性主诉以及与慢性贫血和营养不良有关的问题，超过 2000 万人处于危急状态。

但是，在中国、巴西、埃及和撒哈拉以南非洲部分地区等不同的流行地区，结合了蜗牛控制、水质改善和感染者(尤其是儿童)治疗的重点干预措施已被证明是有效的。已经成功

根据世卫组织的公告，血吸虫病的全球分布正在发生变化。它已在日本和小安的列斯群岛被根除，在突尼斯停止，在沙特阿拉伯、摩洛哥、委内瑞拉和波多黎各非常低。

市场细分。

血吸虫病药物市场可以根据地点、品种类型、药物类别和分销渠道进行细分。

按药物类型来看，□奎酮(Virticide)有望快速增长

□奎酮(杀虫剂)。□奎酮用于治疗血吸虫病，对成虫更有效。□奎酮用于治疗个体患者和大型社区治疗项目。这种药物的作用机制很复杂，会引起超微结构变化并增加对钙离子的渗透性。钙离子在寄生虫的细胞质内积聚，导致成虫肌肉收缩并最终瘫痪。线虫的外膜受损，线虫暴露于患者的免疫反应中，导致线虫死亡。□奎酮的回收率超过85%。在那些没有恢復的人中，卵子负担显着减少。

奥沙尼奎(Vansil)。 Oxamniquin 仅对 S mansoni 有效。这种药物的治愈率约为60-90%。 Oxamniquin 在美国不再可用。奥沙尼奎被偏头痛细菌代谢为酯类。这种药物会破坏雄性半寄生虫的外层皮肤，从而使患者的免疫系统能够杀死该生物体。它还可以阻止雌性寄生虫产卵。手术选择包括肿瘤切除、分流手术和肉芽肿切除。其作用机制复杂。

大多数人类血吸虫病是由血吸虫、曼氏血吸虫和日本血吸虫引起的。不太常见的物种，如 S mekongi 和 S intercalatum 也可引起系统性人类疾病。其他以禽类或哺乳动物为宿主的血吸虫也可导致人类严重的皮炎(例如 Trichobilharzia ocellata)。

地理特征

中东和非洲主导着全球血吸虫病药物市场。

中东和非洲地区在血吸虫病药物市场的份额最大，其次是南美、亚洲、欧洲和北美。南非是中东和非洲地区血吸虫病市场的最大贡献者。在南美，由于患者人数的增加，市场正在迅速扩大，主要是在巴西。然而，预计欧洲和亚太地区在预测期内将增长。大约有 1.2 亿人出现血吸虫病症状，其中 2000 万人患有严重的临床疾病。在撒哈拉以南非洲，每年有超过 20 万人死于血吸虫病。用受感染的水洗衣服的妇女风险很大。卫生和玩泥和水会使儿童更容易受到感染。大约有 4000 万育龄妇女受到感染。非洲约有 1000 万妇女在怀孕期间患有血吸虫病。

在非洲和巴西，难民流向城市地区导致了新的感染地区。由于人口增长和对电力和水的需求增加，感染正在蔓延。大约 5-10% 的流行地区受到严重感染，其余为轻度至中度感染。居住在河流和湖泊附近的人感染的风险最高。在乌干达，在海拔 1400 米或以上且年降雨量小于 900 毫米的地方几乎没有确诊感染。

在西太平洋地区，日本血吸虫肠造口术在菲律宾和中国流行，湄公血吸虫在柬埔寨两省和老挝人民民主共和国一省流行。肠道寄生虫引起腹痛、腹泻和血便。根除该地区的血吸虫病将通过包括健康促进、预防性化疗运动、水和环境卫生 (WASH) 改善、牲畜治疗和管理以及局部蜗牛控制在内的单一健康方法来加强社区。

竞争格局

血吸虫病市场的主要参与者包括 Chemos GmbH &Co.KG、Shin Poong Pharma.Co.Ltd.、Meher Distributors Pvt. Ltd.、Merck &Co.、Salvensis、Bayer AG、LondonPharma Ltd、Merck &Co., Inc., 3S Corporation Kancera AB, Taj Pharmaceuticals Ltd., Avanscure Lifesciences Pvt. Ltd., CBC Pharma., VHB Life Science Inc., Samarth Pharma Pvt. Ltd., Taj Pharmaceuticals Ltd. 和埃及国际製药工业公司 SAE (EIPICO)。这些公司提供多种用于预防性化疗的药物。主要参与者采用了多种增长战略，例如产品发布、收购和合作伙伴关係，这些战略为偏头痛药物市场的全球增长做出了贡献。

2019 年 3 月，IDDO 与热带病研究和培训特别计划 (TDR) 发起了一项新的全球科学合作，专门针对偏头痛和 STH。它旨在扩大数据重用和协作，以加速更好地治疗和管理这些影响全球超过 10 亿人的疾病。

2020 年 1 月，科技领导者默克公司向世界卫生组织 (WHO) 捐赠了 10 亿片□奎酮片，这是治疗血吸虫病的护理标准。这是结束主要影响贫困农村地区儿童的被忽视热带病 (NTD) 的重要里程碑。自 2007 年以来，我们的□奎酮已使撒哈拉以南非洲地区 4 亿学龄儿童得到治疗。

拜耳 K.K.

概述

拜耳公司是一家德国跨国製药和生命科学公司，总部位于勒沃库森。拜耳的业务领域包括人用和兽用药物、消费者保健产品、农用化学品、种子和生物技术产品。製药部门专注于处方药，尤其是女性保健和心血管医学，以及肿瘤学、血液学和眼科领域的特殊药物。我们还有一个放射学业务部门，销售带有造影剂和造影剂的诊断成像系统。

产品组合

BILTRICIDE(□奎酮)。□奎酮是一种用于治疗寄生虫感染的药物。具体而言，它用于血吸虫病、绒毛虫病、后睪症、绦虫感染、囊尾蚴病、包虫病和其他流感感染。不用于寄生虫眼部感染。口服给药。

COVID-19 影响分析

COVID-19 正在通过对生产和需求的直接影响、供应链中断和市场中断以及对企业和金融市场的财务影响来影响全球经济。由于 COVID-19 大流行，全球偏头痛药物市场呈现负增长。这是因为越来越多的利益相关者呼吁采用新的方法来诊断和治疗受 COVID-19 影响的患者。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按产品划分的市场细分
  • 按产品类型划分的市场细分
  • 按药物类型划分的市场细分
  • 按分销渠道划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
  • 驱动程序
    • 血吸虫病发病率上升
  • 限制因素
    • 严格的监管审批
  • 商机
  • 影响分析

第5章行业分析

  • 波特五力分析
  • 管道分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按部分

  • 肠交界处血吸虫病
  • 泌尿生殖系统血吸虫病

第 8 章按物种分类

  • 曼氏原虫
  • 日本血吸虫
  • 湄公血吸虫
  • 几内亚血吸虫
  • 血吸虫

第 9 章按药物类型

  • □奎酮(杀病毒剂)
  • 奥沙尼金(Bancil)
  • 甲磺酸
  • 其他

第 10 章按销售渠道

  • 医院药房
  • 零售药房
  • 在线药店
  • 其他

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 13 章公司简介

  • 拜耳公司
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Merck & Co., Inc.
  • Avanscure Lifesciences Pvt. Ltd.
  • Shin Poong Pharma.Co., Ltd.
  • Egyptian International Pharmaceuticals Industries Co SAE(EIPICO)
  • CBC Pharma.
  • Chemos GmbH & Co. KG.
  • VHB Life Science Inc.
  • 3S Corporation Kancera AB
  • Taj Pharmaceuticals Ltd.(List Not Exhaustive)

第14章 DataM

简介目录
Product Code: DMPH2738

Market Overview

Schistosomiasis Drugs market was valued at USD 70.4 million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 3.8% during the forecast period (2022-2029).

Schistosomiasis, also known as Bilharzia, blood fluke, and Katayama fever, is an acute and chronic disease caused by the parasitic worm Schistosoma genus. The disease is spread through waterborne transmission. The Schistosoma parasites are found in rivers, lakes, water parks, ponds, swimming pools, municipal water, and streams. Infection with S. haematobium, Schistosoma mansoni, and S. japonicum causes illness in humans while less commonly, S. mekongi and S. intercalatum can cause disease. However, the worms that cause schistosomiasis are not found in the United States, but more than 200 million people are infected worldwide. Infection can be spread through direct contact with the infected animal and person. In 2018, schistosomiasis transmission had been reported from 78 countries.

Schistosomiasis symptoms occur when the body reacts to the worms' eggs. Abdominal cramps, diarrhea, blood in the stool, blood in urine, vomiting, liver enlargement, fever, kidney damage, weakness, rash, and body aches are some of the symptoms of the disease. Some other chronic symptoms include genital lesions, vaginal bleeding, and nodules in the vulva. It is recommended by healthcare professionals for repeated examination to confirm the schistosomiasis parasite in the stool and urine. Polymerase chain reaction (PCR) tests and blood tests also help to diagnose schistosomiasis. If no eggs are found in urine or feces other tests such as endoscopy, colonoscopy, echocardiograms, ultrasound, liver biopsy, and MRI, are recommended for better diagnosis. If schistosomiasis is left untreated, it may lead to complications related to the cardiopulmonary, gastrointestinal, central nervous system, spleen, liver, bacterial infections, urinary obstruction, and even death.

Market Dynamics

The global schistosomiasis drugs market growth is driven by factors such as the rising prevalence of schistosomiasis, inadequate healthcare facilities, and lack of safe drinking water in developing countries.

The increasing incidence of Schistosomiasis is driving the market growth

More than 140 million people, 90% of who live in Africa, are infected with schistosomiasis. An estimated 700 million people are at risk of infection in 76 countries where the disease is considered endemic, as their agricultural work, domestic chores, and recreational activities expose them to infested water. Globally, 200,000 deaths are attributed to schistosomiasis annually. Transmission is interrupted in some countries. The World Health Organization (WHO) estimates show that in 2019, about 236.6 million people required preventive treatment for schistosomiasis, out of which more than 105.4 million people were reported to have been treated in 2019.

Hence, the increasing incidence of schistosomiasis is leading to a rise in research and development for its treatment by private manufacturers and research organizations. Several clinical trials are undergoing to expand the potential future of schistosomiasis drugs.

The growing development of novel vaccines for the treatment of schistosomiasis is expected to drive the market growth

On 1st June 2021, The International Vaccine Institute (IVI) received a grant from the Bill & Melinda Gates Foundation to design and develop the adaptive protocol for the phase of Ib/IIa clinical trials for the schistosomiasis vaccine. The vaccine offers in cost-effective and safe. Some vaccines are under development, and some vaccines in patent applications have also been filed in China, India, and Brazil. The development of new vaccines aims to develop and distribute this vaccine at affordable rates for infected people. This development is expected to drive the growth of the schistosomiasis drugs market over the forecast period.

High demand for preventive chemotherapy against schistosomiasis is boosting the schistosomiasis drugs market

As per the World Health Organization (WHO) in 2018, more than 78 countries are constantly infected for schistosomiasis, in which population of 52 countries require preventive chemotherapy. In addition, according to the WHO estimates, in 2018, around 229.2 million people required preventive chemotherapy; among them, around 124.4 million were school-aged children.

However, the high cost of drugs and stringent approval process restrains the market growth. The presence of a large patient pool and unmet medical needs are anticipated to provide lucrative opportunities for market growth.

Epidemiology

In the United States, acute and chronic schistosomiasis infections are not common. However, it is estimated that around 400,000 infected persons have immigrated to the U.S., neither susceptible snail species nor chronically infected human reservoirs sufficient to infest freshwater exists. Pathogenic schistosomes can survive and replicate in human hosts for a long time. Hence, persons who have traveled or immigrated may present to EDs with active cases of acute or chronic schistosomiasis and associated end-organ complications. Most of the infected patients remain asymptomatic. Acute symptoms are more common in nonimmune travelers because of a severe immune response following exposure.

Globally (excluding the United States), schistosomiasis is a major source of mortality and morbidity. Intestinal schistosomiasis caused by S mansoni occurs in about 52 nations, including Caribbean countries (i.e., Puerto Rico, Saint Lucia, Montserrat, Antigua, Martinique, Guadeloupe, Dominican Republic), eastern Mediterranean countries, South American countries (i.e., Brazil, Venezuela, Surinam), and most countries in Africa.

Other Schistosoma species that may cause intestinal symptoms and diseases include S japonicum, S intercalatum, and S mekongi.S intercalatum is found in about ten countries within the rain forests of Central Africa. S japonicum is endemic in 4 countries in the western Pacific region (i.e., China, Indonesia, Philippines, Thailand). S mekongi infection occurs in the Mekong River area of Southeast Asia (i.e., Kampuchea, Laos, Thailand). The urinary schistosomiasis caused by S haematobium affects 54 countries in Africa and the eastern Mediterranean.

Over 207 million people in around 74 countries have the active schistosomal infection. Of this population, around 60% have disease symptoms, including organ-specific complaints and problems related to chronic anemia and malnutrition from the infection; more than 20 million are severely ill.

However, the targeted interventions combining snail control improved water supply quality, and treatment of infected persons, especially children, have shown success in diverse endemic areas, including China, Brazil, Egypt, and some areas of sub-Saharan Africa.

As per the WHO, the global distribution of schistosomiasis has changed. It has been eradicated from Japan and Lesser Antilles islands, the transmission has been stopped in Tunisia, and the transmission is very low in Saudi Arabia, Morocco, Venezuela, and Puerto Rico.

Market Segmentation:

The schistosomiasis drugs market can be segmented based on-site, species type, drug class, and distribution channel.

By Drugs type, Praziquantel (Biltricide) is expected to witness rapid growth

Praziquantel (Biltricide): Praziquantel drug is used to treat schistosomiasis and is more effective on adult worms. Praziquantel is used for the treatment of individual patients and mass community treatment programs. The mechanism of action is complex for this drug as it induces ultrastructural changes resulting in increased permeability to calcium ions. Calcium ions accumulate in the parasite cytosol, which leads to muscle contractions and ultimate paralysis of adult worms. The tegument membrane of the worm is damaged, exposing the worm to the immune response of the patient, which leads to worm death. The recovery rate with praziquantel is more than 85%. In persons not recovered, the egg burden is markedly decreased.

Oxamniquine (Vansil): Oxamniquine is effective only against S mansoni. The cure rate with the drug is around 60-90%. Oxamniquine is no longer available in the United States. Oxamniquine drug is metabolized into an ester by schistosomes. The drug damages the tegument of male schistosome worms so that the immune system of the patient can kill the organisms. It stops female worms from producing eggs. Surgical alternatives can include the removal of tumors, shunt surgeries, and granuloma removal. Its mechanism of action is complex.

Most human schistosomiasis is caused by S haematobium, S mansoni, and S japonicum. Less prevalent species, such as S mekongi and S intercalatum, may also cause systemic human disease. Less importantly, other schistosomes with avian or mammalian primary hosts can cause severe dermatitis in humans (e.g., swimmer's itch secondary to Trichobilharzia ocellata).

Geographical Presentation

The Middle East & Africa is dominating the global schistosomiasis drugs market

The Middle East & Africa region accounted for the largest share of the schistosomiasis drugs market, followed by South America, Asia, Europe, and North America. South Africa is the largest contributor to the schistosomiasis drugs market in Middle East & Africa. The market in South America is expanding rapidly due to an increase in the patient population, especially in Brazil. However, Europe and Asia-Pacific are estimated to grow over the forecast period. Around 120 million people are symptomatic with schistosomiasis, with 20 million having severe clinical disease. Over 200,000 deaths per year are due to schistosomiasis in sub-Saharan Africa. Women washing clothes in infested water are at major risk. Hygiene and playing in mud and water make children vulnerable to infection. Around forty million women of childbearing age are infected. Around 10 million women in Africa have schistosomiasis during pregnancy.

In Africa and Brazil, refugee migration to urban areas is transmitting the disease to new locations. Rising population size and growing needs for power and water have led to increasing transmission. Around 5-10% of an endemic community are heavily infected, and the remainder has mild to moderate infections. The risk of infection is highest amongst those who lived near rivers or lakes. In Uganda, almost no transmission was found to have occurred at altitudes greater than 1400 m or where the annual rainfall was less than 900 mm.

In the Western Pacific Region, intestinal schistosomiasis, caused by Schistosoma japonicum is endemic in the Philippines and China and caused by Schistosoma mekongi is endemic in two provinces in Cambodia and one province in the Lao People's Democratic Republic. Intestinal schistosomiasis can cause abdominal pain, diarrhea, and blood in the stool. Elimination of schistosomiasis in the region is targeted through community empowerment with the One Health approach, composed of health promotion, preventive chemotherapy campaigns, improved water, sanitation and hygiene (WASH), treatment and management of domestic animals, and livestock, and focal snail control.

Competitive Landscape:

Some of the major players in the schistosomiasis treatment market include Chemos GmbH & Co. KG, Shin Poong Pharma. Co. Ltd., Meher Distributors Pvt. Ltd., Merck & Co., Salvensis, Bayer AG, LondonPharma Ltd, Merck & Co., Inc., 3S Corporation Kancera AB, Taj Pharmaceuticals Ltd., Avanscure Lifesciences Pvt. Ltd, CBC Pharma., VHB Life Science Inc., Samarth Pharma Pvt. Ltd., Taj Pharmaceuticals Ltd., and Egyptian International Pharmaceuticals Industries Co SAE (EIPICO). These companies offer various drugs, which are being used for preventive chemotherapy. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the schistosomiasis Drugs market globally.

In March 2019, IDDO launched a new global scientific collaboration dedicated to schistosomiasis and STHs with TDR (the Special Programme for Research and Training in Tropical Diseases). This aims to expand data re-use and collaboration and accelerate better treatment and control of these diseases, which affect more than a billion people globally.

In January 2020, Merck, a leading science and technology company, has donated 1 billion tablets of praziquantel, the standard medication for the treatment of schistosomiasis, to the World Health Organization (WHO). This marks a crucial milestone on the journey to the elimination of this neglected tropical disease (NTD) which mostly affects children in poor and rural communities. Since 2007, the company's praziquantel donations enabled the treatment of 400 million school-aged children in Sub-Saharan Africa.

Bayer AG

Overview:

Bayer AG is a German multinational pharmaceutical and life sciences company headquartered in Leverkusen. Bayer's areas of business include human and veterinary pharmaceuticals; consumer healthcare products; agricultural chemicals, seeds, and biotechnology products. The Pharmaceuticals Division focuses on prescription products, especially for women's healthcare and cardiology, and also on specialty therapeutics in the areas of oncology, hematology, and ophthalmology. The division also comprises the Radiology Business Unit which markets contrast-enhanced diagnostic imaging equipment together with the necessary contrast agents.

Product Portfolio:

BILTRICIDE (praziquantel): Praziquantel is a medication used to treat a number of types of parasitic worm infections. Specifically, it is used for schistosomiasis, clonorchiasis, opisthorchiasis, tapeworm infections, cysticercosis, hydatid disease, and other fluke infections. It should not be used for worm infections of the eye. It is taken by mouth.

COVID-19 Impact Analysis

The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets. The global schistosomiasis drugs market has seen negative growth from the COVID-19 pandemic, as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by the COVID-19.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Site
  • 3.2. Market Snippet by Species Type
  • 3.3. Market Snippet by Drug Type
  • 3.4. Market Snippet by Distribution Channel
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Rising incidence of Schistosomiasis
    • 4.2.2. XX
  • 4.3. Restraints
    • 4.3.1. Stringent regulatory approvals
    • 4.3.2. XX
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Pipeline Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Site

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site Segment
    • 7.1.2. Market Attractiveness Index, By Site Segment
  • 7.2. Intestinal Schistosomiasis*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3. Urogenital schistosomiasis

8. By Species Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type Segment
    • 8.1.2. Market Attractiveness Index, By Species Type Segment
  • 8.2. Schistosoma mansoni*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3. Schistosoma japonicum
  • 8.4. Schistosoma mekongi
  • 8.5. Schistosoma guineensis
  • 8.6. Schistosoma haematobium

9. By Drug Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
    • 9.1.2. Market Attractiveness Index, By Drug Type Segment
  • 9.2. Praziquantel (Biltricide)*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 9.3. Oxamniquine (Vansil)
  • 9.4. Metrifonate
  • 9.5. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies
  • 10.5. Others

11. By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Bayer AG*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Merck & Co., Inc.
  • 13.3. Avanscure Lifesciences Pvt. Ltd.
  • 13.4. Shin Poong Pharma.Co., Ltd.
  • 13.5. Egyptian International Pharmaceuticals Industries Co SAE (EIPICO)
  • 13.6. CBC Pharma.
  • 13.7. Chemos GmbH & Co. KG.
  • 13.8. VHB Life Science Inc.
  • 13.9. 3S Corporation Kancera AB
  • 13.10. Taj Pharmaceuticals Ltd. (List Not Exhaustive)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us